GlassScriptPhysician profile
Michael David Brown
NPI 1215479241
$3,024.09
in general payments reported to CMS, 2019-2025
37 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,754 · 2022: $31.44 · 2023: $15.73 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $355.04 | 2021-2025 | Airsupra, Fasenra, Breztri |
| Novo Nordisk INC | $313.25 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $212.06 | 2025 | Bylvay, Iqirvo |
| Lilly USA, LLC | $186.14 | 2021 | |
| Abbvie INC. | $175.40 | 2021 | |
| Madrigal Pharmaceuticals | $171.52 | 2025 | Rezdiffra |
| Amgen INC. | $159.22 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.49 | 2021-2025 | Glassia |
| Intercept Pharmaceuticals, INC. | $124.36 | 2025 | |
| Glaxosmithkline, LLC. | $120.00 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Biohaven Pharmaceuticals, INC. | $118.69 | 2021 | |
| Intuitive Surgical, INC. | $118.11 | 2025 | |
| Merck Sharp & Dohme LLC | $111.92 | 2021 | |
| Galvanize Therapeutics, INC | $100.91 | 2025 | Aliya System |
| Pfizer INC. | $71.22 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $65.26 | 2021 | |
| Supernus Pharmaceuticals, INC. | $54.80 | 2021 | |
| Currax Pharmaceuticals LLC | $39.26 | 2021 | |
| Viatris Specialty LLC | $39.03 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $29.55 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $29.18 | 2021 | |
| Adlon Therapeutics L.P. | $26.30 | 2021 | |
| Inspire Medical Systems, INC. | $25.22 | 2025 | Inspire |
| Harmony Biosciences LLC | $21.71 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.00 | 2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $19.85 | 2021 | |
| Ani Pharmaceuticals, INC. | $17.97 | 2025 | Purified Cortrophin Gel |
| Electromed, INC. | $17.27 | 2025 | Smartvest |
| Axsome Therapeutics, INC. | $16.85 | 2025 | Sunosi |
| Mallinckrodt Hospital Products INC. | $16.04 | 2025 | Acthar |
| Esperion Therapeutics, INC. | $14.13 | 2021 | |
| Genzyme Corporation | $14.10 | 2025 | |
| Gilead Sciences, INC. | $14.07 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.95 | 2021 | |
| Cranial Technologies, INC | $13.43 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.46 | 2021 | |
| Corium, LLC | $7.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.